Muglu H, Sunger E, Koylu B, Tunali D, Erol C, Selcukbiricik F
Medicina (Kaunas). 2025; 61(2).
PMID: 40005418
PMC: 11857675.
DOI: 10.3390/medicina61020302.
Bonaca M, Lang N, Chen A, Amiri-Kordestani L, Lipka L, Zwiewka M
JACC CardioOncol. 2025; 7(2):83-95.
PMID: 39967209
PMC: 11866450.
DOI: 10.1016/j.jaccao.2024.09.014.
Huang Y, Sun Y, Chou H, Wagner N, Vitale M, Bayer A
Circ Res. 2025; 136(5):473-490.
PMID: 39931812
PMC: 11867805.
DOI: 10.1161/CIRCRESAHA.124.325652.
Leong D, Waliany S, Abdel-Qadir H, Atkins K, Neilan T, Lang N
JACC CardioOncol. 2025; 6(6):815-834.
PMID: 39801647
PMC: 11711816.
DOI: 10.1016/j.jaccao.2024.06.005.
Kwan J, Shen M, Akhlaghi N, Hu J, Mora R, Cross J
PLoS One. 2024; 19(12):e0314555.
PMID: 39621799
PMC: 11611253.
DOI: 10.1371/journal.pone.0314555.
Evaluating Troponin-Based Monitoring in Patients Undergoing Immune Checkpoint Inhibitor Therapy.
Tamura Y, Tamura Y
JACC Adv. 2024; 3(12):101374.
PMID: 39583871
PMC: 11584775.
DOI: 10.1016/j.jacadv.2024.101374.
Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors: Data From a Prospective Study.
van den Berg P, Bracun V, Noordman M, van der Meer P, Shi C, Oosting S
JACC Adv. 2024; 3(12):101375.
PMID: 39583866
PMC: 11584941.
DOI: 10.1016/j.jacadv.2024.101375.
Cardiac Troponin I and T in ICI Myocarditis Screening, Diagnosis, and Prognosis.
Barac A, Wadlow R, Deeken J, deFilippi C
JACC CardioOncol. 2024; 6(5):804-807.
PMID: 39479330
PMC: 11520212.
DOI: 10.1016/j.jaccao.2024.07.001.
Cardiovascular Considerations Before Cancer Therapy: Gaps in Evidence and Expert Panel Recommendations.
Raisi-Estabragh Z, Murphy A, Ramalingam S, Scherrer-Crosbie M, Lopez-Fernandez T, Reynolds K
JACC CardioOncol. 2024; 6(5):631-654.
PMID: 39479317
PMC: 11520216.
DOI: 10.1016/j.jaccao.2024.07.017.
Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors.
Cheema P, Iafolla M, Abdel-Qadir H, Bellini A, Chatur N, Chandok N
Curr Oncol. 2024; 31(10):6356-6383.
PMID: 39451777
PMC: 11506662.
DOI: 10.3390/curroncol31100473.
Myocarditis Induced by Immune Checkpoint Inhibitors: An Exploratory Review.
Zavaleta-Monestel E, Garcia-Montero J, Anchia-Alfaro A, Rojas-Chinchilla C, Quesada-Villasenor R, Arguedas-Chacon S
Cureus. 2024; 16(8):e67314.
PMID: 39301338
PMC: 11412606.
DOI: 10.7759/cureus.67314.
Genetic factors in the pathogenesis of cardio-oncology.
Qi Y, Wei Y, Li L, Ge H, Wang Y, Zeng C
J Transl Med. 2024; 22(1):739.
PMID: 39103883
PMC: 11301970.
DOI: 10.1186/s12967-024-05537-5.
Close Cardiovascular Monitoring during the Early Stages of Treatment for Patients Receiving Immune Checkpoint Inhibitors.
Delombaerde D, Vulsteke C, Van de Veire N, Vervloet D, Moerman V, Van Calster L
Pharmaceuticals (Basel). 2024; 17(7).
PMID: 39065813
PMC: 11279915.
DOI: 10.3390/ph17070965.
Adverse myocardial and vascular side effects of immune checkpoint inhibitors: a prospective multimodal cardiovascular assessment.
Mirabel M, Eslami A, Thibault C, Oudard S, Mousseaux E, Wahbi K
Clin Res Cardiol. 2024; 113(8):1263-1273.
PMID: 38806821
DOI: 10.1007/s00392-024-02462-x.
Pumping Up the Standards: A Call for Improved Cardiovascular Event Reporting in Oncology Trials.
Kappel C, Abdel-Qadir H, Nadler M
JACC CardioOncol. 2024; 6(2):280-282.
PMID: 38774007
PMC: 11103042.
DOI: 10.1016/j.jaccao.2024.01.010.
Clinical Interpretation of Serum Troponin in the Era of High-Sensitivity Testing.
Maayah M, Grubman S, Allen S, Ye Z, Park D, Vemmou E
Diagnostics (Basel). 2024; 14(5).
PMID: 38472975
PMC: 10930800.
DOI: 10.3390/diagnostics14050503.
Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach.
Murtagh G, deFilippi C, Zhao Q, Barac A
Front Cardiovasc Med. 2024; 11:1350585.
PMID: 38410245
PMC: 10894940.
DOI: 10.3389/fcvm.2024.1350585.
Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.
Shalata W, Steckbeck R, Abu Salman A, Abu Saleh O, Abu Jama A, Attal Z
Medicina (Kaunas). 2024; 60(2).
PMID: 38399513
PMC: 10890382.
DOI: 10.3390/medicina60020224.
Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure.
Gergely T, Drobni Z, Kallikourdis M, Zhu H, Meijers W, Neilan T
Nat Rev Cardiol. 2024; 21(7):443-462.
PMID: 38279046
DOI: 10.1038/s41569-023-00986-9.
Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers.
Miao Y, Quan W, Tang X, Shi W, Li Q, Li R
Int J Biol Sci. 2024; 20(2):621-642.
PMID: 38169638
PMC: 10758091.
DOI: 10.7150/ijbs.89376.
